It was shown the levels and positive rates of serum anti-TIF1γ-IgM and anti-TIF1γ-IgE in early LC group had no significant difference from that in LBL group and HC group (P>0.05), while the levels and positive rates of anti-TIF1γ-IgA and anti-TIF1γ-IgG were significantly higher than that in LBL group and HC group (P<0.01), of which anti-TIF1γ-IgA presented the AUC of 0.704 for the patients with LC at early stage, with 28.20% sensitivity at 95.93% specificity, and anti-TIF1γ-IgG presented the AUC of 0.622 for the patients with LC at early stage, with 18.54% sensitivity at 94.25% specificity. The gene discussed is CD79A; the disease is laryngotracheoesophageal cleft.